EBMT 2019 | CD19 CAR T-cell therapy for lymphoma
Michael Schmitt, MHBA, of University Hospital Heidelberg, Germany discusses CD19 CAR T-cell therapy against acute- and non-Hodgkin lymphoma. Being the 4th trial of its kind worldwide, Prof. Schmitt examines the need for new technology therapies to prevent patient relapse. This interview took place at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting 2019, held in Frankfurt, Germany.
Get great new content delivered to your inboxSign up